Chargement en cours...
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
BACKGROUND: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors. METHODS: We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa inhibitor. The patients received a bolus of andexa...
Enregistré dans:
| Publié dans: | N Engl J Med |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6699827/ https://ncbi.nlm.nih.gov/pubmed/30730782 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1814051 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|